Patterns of care for pediatric patients with newly-diagnosed grade II gliomas

Childs Nerv Syst. 2021 May;37(5):1563-1572. doi: 10.1007/s00381-020-05002-w. Epub 2021 Jan 6.

Abstract

Purpose: We describe large-scale demographic, initial treatment, and outcomes data for pediatric grade II gliomas included in the National Cancer Database from 2004 to 2014.

Methods: Our cohort included cases less than 21 years of age with pathology-confirmed disease. Logistic regressions were used to evaluate the use of chemotherapy (CT) and radiation therapy (RT). Overall survival (OS) rates were determined using Kaplan-Meier estimates and the log-rank test.

Results: We identified 803 cases with astrocytoma (56.2%), oligodendroglioma (26.0%), and mixed glioma/glioma NOS (17.8%) histologies. Most cases underwent surgical resection (n = 661). Whereas cases 16 to 21 years of age were more likely than cases 0 to 5 years to receive RT (OR = 7.38, 95% CI 3.58-15.21, p < 0.001), they were less likely to receive CT (OR = 0.34, 95% CI 0.22-0.52, p < 0.001). The 5-year OS rates for all cases, cases that underwent surgical resection, and cases managed with biopsy were 87.5%, 92.7%, and 63.6%, respectively.

Conclusion: In one of the largest series of pediatric grade II gliomas, astrocytoma was the most common histology. Patterns of care and OS outcomes were similar to grade I gliomas, with surgical resection being the most common initial treatment and associated with a favorable rate of OS. Younger patients were more likely to receive post-operative CT and the use of RT increased with age.

Keywords: Brain tumors; Gliomas; Grade II; Pediatrics.

MeSH terms

  • Adult
  • Astrocytoma*
  • Brain Neoplasms* / diagnosis
  • Brain Neoplasms* / therapy
  • Child
  • Child, Preschool
  • Glioma* / diagnosis
  • Glioma* / therapy
  • Humans
  • Infant
  • Infant, Newborn
  • Kaplan-Meier Estimate
  • Oligodendroglioma*